Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,599.35INR
11:27am BST
Change (% chg)

Rs-33.15 (-1.26%)
Prev Close
Rs2,632.50
Open
Rs2,640.00
Day's High
Rs2,644.65
Day's Low
Rs2,580.45
Volume
480,116
Avg. Vol
674,581
52-wk High
Rs2,964.00
52-wk Low
Rs1,872.95

Summary

Name Age Since Current Position

Satish Reddy

50 2014 Chairman of the Board

G. Prasad

57 2014 Co-Chairman of the Board, Chief Executive Officer, Managing Director

Saumen Chakraborty

56 2018 President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE

MARC KIKUCHI

50 2019 Chief Executive Officer, North America Generics

M. Ramana

51 2018 Chief Executive Officer, Branded Markets (India and Emerging Markets)

Erez Israeli

52 2018 Chief Operating Officer and Global Head of Generics & PSAI

Archana Bhaskar

52 2017 Chief Human Resource Officer

Raymond De Vre

51 2017 Global Head of Biologics

Sauri Gudlavalleti

41 2018 Global Head of Integrated Product Development Organization

Ganadhish Kamat

57 2016 Global Head of Quality

Anil Namboodiripad

53 2007 Global Head of Proprietary Products

YUGANDHAR PUVVALA

48 2018 Global Head of Supply Chain

Deepak Sapra

44 2018 Global Head of PSAI

SANJAY SHARMA

51 2017 Global Head of Manufacturing

Sandeep Poddar

2018 Company Secretary

Bruce Carter

75 2008 Non-Executive Independent Director

Bharat Doshi

70 2016 Non-Executive Independent Director

Omkar Goswami

62 2000 Non-Executive Independent Director

Sridar Iyengar

71 2011 Non-Executive Independent Director

Prasad Menon

73 2017 Non-Executive Independent Director

Kalpana Morparia

70 2007 Non-Executive Independent Director

Allan Oberman

61 2019 Non-Executive Independent Director

Anupam Puri

2002 Non-Executive Independent Director

Leo Puri

58 2018 Non-Executive Independent Director

Shikha Sharma

60 2019 Non-Executive Independent Director

Saunak Savla

2016 IR Contact Officer

Biographies

Name Description

Satish Reddy

Mr. Satish K. Reddy serves as a Chairman of the Board of the Company. Mr. K Satish Reddy joined the company in 1993 as Executive Director and since then has held positions of increasing responsibility as Managing Director in 1997 and Vice-Chairman & Managing Director in 2013. Mr. Reddy led the company’s transition from a uni-focused manufacturer of Active Pharmaceutical Ingredients (APIs) to a company that moved up the value chain with a diverse product portfolio of fi nished dosage formulations. He oversaw the expansion and the establishment of a strong footprint for Dr. Reddy’s fi nished dosage products in Russia, CIS countries and other emerging markets. Keeping true to the legacy of the founder of the company, Dr. K Anji Reddy, Mr. K Satish Reddy drives the company’s Corporate Social Responsibility initiatives. Mr. Reddy holds a degree in Chemical Engineering from Osmania University, Hyderabad and a Masters in Medicinal Chemistry from Purdue University, USA.

G. Prasad

Mr. G. V. Prasad serves as a Co-Chairman of the Board, Chief Executive Officer, Managing Director of the Company. Mr. G V Prasad leads the core team at Dr. Reddy’s that has contributed signifi cantly to its transformation from a mid-sized domestic operation into a global pharmaceutical major. He is the architect of Dr. Reddy’s successful Global Generics and Active Pharmaceutical Ingredient (API) strategies, as well as the company’s foray into biosimilars and diff erentiated formulations. Mr. Prasad is engaged with strengthening the company’s research and development capabilities, supporting progressive people practices and building a holistic culture of operational excellence. He was listed in the prestigious ‘Medicine Maker 2018 Power List’ of most inspirational professionals shaping the future of drug development, and one of ‘India’s Greatest 50 CEOs Ever’ by Outlookmagazine in 2017. Mr. Prasad holds a degree in Chemical Engineering from the Illinois Institute of Technology, Chicago, USA and a Masters in Industrial Administration from Purdue University, USA.q

Saumen Chakraborty

Mr. Saumen Chakraborty is President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE of the Company. He has been appointed as Chief Financial Officer of the company effective January 2, 2013. In this role, he is responsible for Company's Information Technology, Business Process Excellence, Corporate Communications and Supply Chain Effectiveness functions. Prior to this role, he was head of the Global Generics Operations along with Integrated Product Development across the organization. Mr. Chakraborty joined the Company in 2001 as Global Chief of Human Resources. He later took over as Chief Financial Officer in 2006 and then became Company's President — Corporate and Global Generics Operations in early 2009. He has 26 years of experience in strategic and operational aspects of management. Prior to joining the Company, he held various line manager, human resources and other positions, including Senior Manager (Finance and Accounts) in Eicher, and Vice President (Operations) in Tecumseh. A member of various industry forums, including the Confederation of Indian Industry and the National HRD Network, he graduated with honors as the valedictorian of his class from Visva-Bharati University in Physics, and went on to pursue management from the Indian Institute of Management, Ahmedabad.

MARC KIKUCHI

M. Ramana

Mr. M. V. Ramana serves as an Chief Executive Officer, Branded Markets (India and Emerging Markets) of the Company. He was Senior Vice President, Head - Emerging Markets, Global Generics of Dr.Reddy's Laboratories Ltd. Ramana has an MBA degree from Osmania University, Hyderabad.

Erez Israeli

Mr. Erez Israeli is a Chief Operating Officer and Global Head of Generics & PSAI of the Company. In a career spanning over 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including Vice President Marketing & Sales for North America, Vice President Asia Operations, President Teva API, Group Executive Vice President, Head of Global Quality, and President & CEO Growth Markets.

Archana Bhaskar

Raymond De Vre

Sauri Gudlavalleti

Ganadhish Kamat

Anil Namboodiripad

YUGANDHAR PUVVALA

Deepak Sapra

SANJAY SHARMA

Sandeep Poddar

Bruce Carter

Dr. Bruce L. A. Carter, Ph.D., serves as a Non-Executive Independent Director of the Company. Dr. Bruce L A Carter was the Chairman of the Board and Chief Executive Offi cer of ZymoGenetics Inc., USA. He has also served as the Corporate Executive Vice President and Chief Scientifi c Offi cer for Novo Nordisk A/S. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Limited. He was a lecturer at Trinity College, University of Dublin, from 1975 to 1982. Dr. Carter holds directorship in Enanta Pharmaceutical Inc., Mirati Therapeutics Inc., Accelerator Corporation and TB Alliance, all in the US and our wholly-owned subsidiary, Aurigene Discovery Technologies Limited, in India. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England and a Ph.D. in Microbiology from Queen Elizabeth College, London University, UK.

Bharat Doshi

Mr. Bharat Narotam Doshi serves as a Non-Executive Independent Director of the company. He joined our Board in May 2016. He is a former Executive Director and Group CFO of Mahindra & Mahindra Limited. He was also the Chairman of Mahindra & Mahindra Financial Services Limited since April 2008 and he stepped down from this position on his nomination as Director on the Central Board of Directors of the Reserve Bank of India in March 2016. He is the Chairman of Mahindra Intertrade Limited and a Director on the Board of Mahindra Holdings Limited. He is also an Independent Director of Godrej Consumer Products Limited. He also serves on the Advisory Board of Excellence Enablers, an organisation committed to promoting corporate governance in India. Mr. Doshi is a Fellow Member of the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India and holds a Master’s degree in Law from Bombay University. He is an alumnus of Harvard Business School (PMD) and Fellow of the Salzburg Seminar on ‘Asian Economies: Regional and Global Relationships’.

Omkar Goswami

Dr. Omkar Goswami, Ph.D., serves as a Non-Executive Independent Director of the Company. Dr. Omkar Goswami is the Founder and Chairman of CERG Advisory Private Limited, a corporate advisory and economic research and consulting company. He was the Chief Economist at the Confederation of Indian Industry for six years. He also served as editor of Business India, Associate Professor at the Indian Statistical Institute, Delhi, and as an advisor to the Ministry of Finance. Dr. Goswami holds directorship in CG Power and Industrial Solutions Limited, Ambuja Cements Limited, Godrej Consumer Products Limited, Bajaj Finance Limited, Hindustan Construction Company Limited, Bajaj Auto Limited and CERG Advisory Private Limited. He holds a Bachelor of Economics degree from Calcutta University, India and did his Masters in Economics from the Delhi School of Economics, India and his D. Phil. (Ph. D.) from Oxford University, UK.

Sridar Iyengar

Mr. Sridar A. Iyengar serves as Non-Executive Independent Director of Dr. Reddy's Laboratories Ltd. Mr. Sridar Iyengar is an independent mentor investor in early stage start- ups and companies. Earlier, he was a senior partner with KPMG in the US and UK and also served as the Chairman & CEO of KPMG’s operations in India. For more than 35 years, he has worked with a large number of companies, advising them on strategy and other issues. Mr. Iyengar holds directorship in Mahindra Holidays and Resorts India Limited, ICICI Venture Funds Management Company Limited, Cleartrip Private Limited in India; AverQ Inc. in the US; Cleartrip Inc. in Cayman Islands; Holiday Club Resorts OY in Finland and our wholly-owned subsidiary, Dr. Reddy’s Laboratories S.A., in Switzerland. He holds a Bachelor of Commerce (Hons.) degree from Calcutta University, India and is a Fellow of the Institute of Chartered Accountants in England and Wales.

Prasad Menon

Mr. Prasad Raghava Menon serves as Non-Executive Independent Director of the Company. Mr. Prasad R Menon is a former Managing Director of Tata Chemicals Limited and Tata Power Company Limited. Prior to joining Tata, he was Director Technical of Nagarjuna Fertilisers and Chemicals Limited. He has over 40 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry. Mr. Menon holds directorship in Singapore Tourism Board and Sanmar Group Advisory Board. Mr. Menon holds a chemical engineering degree from the Indian Institute of Technology (IIT), Kharagpur, India.

Kalpana Morparia

Ms. Kalpana Morparia serves as Non-Executive Independent Director of Dr. Reddy's Laboratories Ltd. Ms. Kalpana Morparia is the Chair person of J.P. Morgan, South and Southeast Asia. Ms. Morparia is a member of J.P. Morgan’s Asia Pacifi c Management Committee. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group Companies and was the Joint Managing Director of ICICI Group from 2001 to 2007. She has been recognized by several nationaland international media for her role as one of the leading women professionals. Ms. Morparia holds directorship in Hindustan Unilever Limitedand J.P. Morgan Services India Private Limited in India and Philip Morris International Inc. in USA. She is also a member of the Governing Board of Bharti Foundation. A graduate in science and law from Mumbai University, India. Ms. Morparia has served on several committees constituted by the Government of India.

Allan Oberman

Mr. Allan Oberman is Non-Executive Independent Director of the Company. Mr. Allan Oberman served as the Chief Executive Offi cer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Limited. Prior to that, Mr. Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010, he served as the Chief Operating Offi cer of the Teva International Group, and from 2000 to 2008, he served as the President and CEO of Teva Canada (formerly Novopharm Limited). From 1996 to 2000, Mr. Oberman was the President of Best Foods Canada Inc. He holds directorship in Planet Shrimp Inc. and Jay Pharma Inc., both in Canada. He has an MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.

Anupam Puri

Mr. Anupam P. Puri serves as a Non-Executive Independent Director of the Company. Mr. Anupam Puri was associated with McKinsey & Company before joining us. He spearheaded the development of McKinsey’s India practice, oversaw the Asian and Latin American offi ces, and was an elected member of the Board. He played a variety of other leadership roles during his 30-year career there. Before joining McKinsey and Company, he was Advisor for Industrial Development to the President of Algeria, and consultant to General Electric’s Center for Advanced Studies. He is currently a management consultant. Mr. Puri holds directorship in Mahindra & Mahindra Limited, Tech Mahindra Limited, and the company’s wholly-owned subsidiary, Dr. Reddy’s Laboratories Inc., USA. Mr. Puri holds an M.Phil. in Economics from Nuffi eld College, Oxford University, UK, an M.A. in Economics from Balliol College, Oxford University, UK and a B.A. in Economics from Delhi University, India.

Leo Puri

Mr. Leo Puri is Non-Executive Independent Director of the Company. Mr. Leo Puri was the Managing Director of UTI Asset Management Co. Limited from August 2013 to August 2018. In his career of more than 30 years, Mr. Puri has previously worked as Director with McKinsey & Company and as Managing Director with Warburg Pincus. Mr. Puri has worked in the UK, USA and Asia. Since 1994, he has primarily worked in India. At McKinsey, he has advised leading fi nancial institutions, conglomerates and investment institutions in strategy and operational issues. He has contributed to the development of knowledge and public policy through advice to regulators and government offi cials. At Warburg Pincus, he was responsible for leading and managing investments across industries in India. He also contributed to fi nancial services investments in the international portfolio as a member of the global partnership. Mr. Puri holds directorship in Hindustan Unilever Limited, Northern Arc Capital Limited and Indiaideas.com Limited (Billdesk). Mr. Puri has a Master’s degree in P.P.E. from Oxford University, UK and a Master’s degree in Law from Cambridge University, UK.

Shikha Sharma

Smt. Shikha Sharma is Non-Executive Independent Director of the Company. Ms. Shikha Sharma was the Managing Director & CEO of Axis Bank, India’s third largest private sector bank from June 2009 upto December 2018. As a leader adept at managing change, she led the Bank on a transformation journey from being primarily a corporate lender to a bank with a strong retail deposit franchise and a balanced lending book. Ms. Sharma has more than three decades of experience in the fi nancial sector, having begun her career with ICICI Bank Limited in 1980. During her tenure with the ICICI Group, she was instrumental in setting up ICICI Securities. As Managing Director & CEO of ICICI Prudential Life Insurance Company Limited, she led the company to become the No. 1 private sector life insurance company in India. Ms. Sharma holds directorships in Ambuja Cements Limited and Tata Global Beverages Limited. Ms. Sharma has an MBA from the Indian Institute of Management, Ahmedabad, India, B.A. (Hons.) in Economics and PGD in Software Technology from National Centre for Software Technology (NCST), Mumbai, India.

Saunak Savla